Semaglutide sulfur burps are belches with a rotten-egg smell, usually noticed after starting semaglutide or moving to a higher dose. Semaglutide can slow the early movement of food out of the stomach. That creates more opportunity for fullness, reflux and gas, while gut bacteria can produce the sulfur-containing gas hydrogen sulfide. The connection is plausible, but not proven in a sulfur-burp study.
The reassuring part is that belching is a documented semaglutide adverse effect and gastrointestinal symptoms often ease after the dose has been stable. The important limit is that persistent vomiting or severe abdominal pain is not something to explain away as ordinary burping.
What semaglutide sulfur burps are
Eructation is the clinical word for belching. A sulfur burp is eructation whose odor resembles rotten eggs, the familiar smell associated with hydrogen sulfide. It may arrive with early fullness, bloating, reflux, nausea or a taste of food eaten hours earlier. It is not a separate diagnosis.
That distinction matters when reading trial data. Semaglutide studies recorded eructation, not the odor of each event. They tell us how often participants reported belching, but they cannot tell us the percentage who had the sulfur-smelling version. Online anecdotes cannot fill that gap because they have no denominator and may overrepresent memorable symptoms.
Burping alone is generally a tolerability issue. A broader guide to semaglutide side effects covers the medication's full adverse-effect profile without treating every digestive symptom as the same problem.
Why semaglutide can produce the smell
Semaglutide activates the GLP-1 receptor and changes gastrointestinal movement. In a randomized crossover study of 30 adults with obesity, first-hour gastric emptying after a meal was 27% lower after 12 weeks of semaglutide than after placebo, although total emptying over five hours was not significantly different (Hjerpsted et al., Diabetes, Obesity and Metabolism, 2018). This is one reason a meal may feel as though it sits longer.
Hydrogen sulfide is the odor part of the explanation. Gut bacteria can generate sulfide from sulfur-containing material in the digestive tract. In a small controlled feeding study, fecal sulfide rose as dietary meat increased, supporting protein as one substrate for bacterial sulfide production (Magee et al., American Journal of Clinical Nutrition, 2000).
Put those findings together and a reasonable model emerges: slower upper-gut movement promotes retained food, pressure and belching, while bacterial metabolism supplies sulfurous gas. It remains a model. No clinical trial has measured hydrogen sulfide in burps before and after semaglutide, and gas made in the colon does not by itself prove where a burp originated.
How common are semaglutide sulfur burps?
The sulfur-specific rate is unknown. The best numbers are for eructation overall, and they vary with the population and semaglutide regimen.
| Trial population | Semaglutide | Placebo | What was counted |
|---|---|---|---|
| STEP-program adults with obesity or overweight | 7% | Less than 1% | Eructation |
| Placebo-controlled SUSTAIN-program diabetes pool, 0.5 mg | 2.7% | 0% | Eructation |
| Placebo-controlled SUSTAIN-program diabetes pool, 1 mg | 1.1% | 0% | Eructation |
The STEP-program figures come from the current Wegovy prescribing information, which pooled 2,116 treated adults and 1,261 placebo recipients. The diabetes figures appear in the current Ozempic prescribing information. Rates from different doses and trial populations are not directly comparable, and none identifies sulfur odor.
Timing is clearer than smell. A pooled analysis of STEP 1–3 found that gastrointestinal events were usually mild to moderate, transient, and most frequent during or shortly after dose escalation (Wharton et al., Diabetes, Obesity and Metabolism, 2022). Belching was not charted separately over time, so there is no evidence-based promise that sulfur burps resolve on a particular day. The pattern often improves at a stable dose, but persistence deserves a prescriber conversation. How long GLP-1 nausea lasts explains the related escalation pattern.
Tirzepatide can also produce eructation because it includes GLP-1 receptor activity; its 2026 prescribing information reports 4%–5% across weight-management doses versus 1% with placebo. It is a related option, but switching does not ensure the belching will stop. Tirzepatide diarrhea covers a different bowel symptom that should not be used as a proxy for sulfur burps.
What a prescriber may discuss for sulfur burps
Management starts with reducing the amount of food the slowed stomach must handle at once. A prescriber may discuss smaller meals, slower eating, stopping at comfortable fullness, and less high-fat food while symptoms are active. Fluids taken steadily in smaller amounts may be easier to tolerate than a large drink with a large meal. A 2025 Mayo Clinic Proceedings review describes smaller, more frequent meals, adequate hydration and avoidance of high-fat foods as first-line management for GLP-1 gastrointestinal effects (Saha et al., 2025).
Food patterns are individual. Eggs, meat, dairy, onions, garlic and cruciferous vegetables all contain sulfur compounds, but eliminating all of them can unnecessarily narrow protein, fiber and micronutrient intake. A short record of meal size, fat content, suspected sulfur-rich foods, injection timing and symptoms can help a clinician identify a repeatable trigger. When one high-sulfur food reliably tracks with symptoms, temporary reduction may be more useful than broad elimination. The goal is a targeted adjustment, not permanent removal of nutritious food.
If symptoms began after escalation, the prescriber may consider holding longer at the current dose or changing the plan. Whether to pause titration or change dose is a clinical decision for the patient and prescriber, not a home experiment. At Promise, a licensed provider reviews every request, and not everyone qualifies for semaglutide.
When burps need medical attention
Sulfur odor alone is not the red flag. The accompanying symptoms are. Persistent vomiting, an inability to keep fluids down, signs of dehydration, or severe or persistent abdominal pain call for prompt medical assessment. Pain that does not go away, especially if it reaches the back or comes with vomiting, is among the pancreatitis symptoms described in the current Wegovy prescribing information.
A swollen abdomen with worsening pain, repeated vomiting, or inability to pass stool or gas also needs urgent evaluation. Those patterns are different from an occasional unpleasant belch. A clinician can assess whether the issue is medication tolerability, reflux, delayed emptying, infection, gallbladder or pancreatic disease, or another gastrointestinal condition rather than assuming semaglutide explains everything.